Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast Cancer Res Treat
Egile Nagusiak: Yao, Katharine, Goldschmidt, Robert, Turk, Mary, Wesseling, Jelle, Stork-Sloots, Lisette, de Snoo, Femke, Cristofanilli, Massimo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2015
Gaiak:
Clinical Trial
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4621695/
https://ncbi.nlm.nih.gov/pubmed/26424167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3587-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak